Digestive Disease Week® (DDW) is one of the largest meetings for the GI professional and attracts 15,000 physicians, researchers and academicians each year. At DDW you'll learn about new developments in your field, attend high-quality educational programs and network with colleagues.
The AASLD Meeting at DDW provides a forum for the exchange of groundbreaking research and clinical information in diseases of the liver and biliary tract and in liver transplantation. This will be done in a variety of formats, including plenary and parallel sessions, courses, workshops and state-of-the-art lectures.
DDW is co-sponsored by AASLD, AGA, ASGE and SSAT.
For more information about AASLD’s programming, see DDW’s Online Preliminary Program.
The management of chronic liver disease continues to evolve with licensing of several new regimens to treat chronic HCV infection. In addition, therapeutic advances continue in other areas with clinical trials clarifying the potential to treat NAFLD with specific therapies rather than merely addressing its precipitants. In chronic HBV infection agents in clinical trials hold the promise of curative rather than suppressive therapy. In patients with portal hypertension more nuanced prophylaxis helps prevent additional complications. This activity will offer a succinct uptake on key advances in hepatology.
The goals of this clinical symposium are to inform attendees on the current state of the art as it pertains to diet and exercise recommendations for NASH. Attendees will also get an update on the current therapeutic landscape for NASH, including mechanism of action, target engagement, efficacy and timelines for potential FDA-approved medications.
The current era of hepatology is one where genetic contributions to etiology and course of cholestatic liver disease are becoming more evident. Application of new, CLIA-approved, sequencing technologies have not only found new diseases, but also have worked into day-to-day clinical diagnostic algorithms in both pediatrics and adult medicine. Thus, current diagnostic opportunities that include single gene sequencing, gene panels and whole exome/genome sequencing present the clinician with perhaps too many choices. This symposium will help participants understand and utilize these new choices.
Direct-acting antiviral agents can safely cure virtually all individuals with HCV infection and offer the chance to eradicate this disease in the United States. The gastroenterologist can play a pivotal role in treating hepatitis C in populations traditionally referred within their specialty. Importantly, they may also serve as a critical resource for collaboration with other health care providers who manage HCV patients at different access points within the HCV care cascade. This symposium will review the latest DAA therapies and how they are integrated into clinical practice, review the changing epidemiology of HCV, and discuss the role that gastroenterologists may play in developing strategies and implementation processes that will maximize the number of individuals who are treated for chronic hepatitis C.
This symposium aims to address important clinical challenges in the diagnosis and treatment of NASH across the age spectrum. Speakers will focus on areas of controversy in addition to discussing emerging concepts in diagnostics and therapeutics.
The successful development of antiviral therapies for chronic HBV and HCV has revealed a remarkable capacity of the liver to regenerate and resorb scar, indicating that it harbors potent endogenous antifibrotic pathways. By exploiting these emerging pathways, we anticipate the development of novel antibiotic therapies that may be able to successfully reduce fibrosis deposition and accelerate its removal without curing the underlying disease. However, we need a greater understanding of the clinical features and determinants of fibrosis regression to develop new diagnostic tools and therapies. This symposium will highlight important, emerging concepts that enable us to predict and refine our understanding of fibrosis regression. Ultimately, these advances will transform the diagnosis and management of chronic fibrotic liver diseases and offer new prospects for improving the outlook of patients with these conditions.
The goals of this clinical symposium will be to educate attendees on important aspects of caring for patients with cirrhosis at the bedside. This is a case based discussion of the difficult aspects of caring for a patient with end stage liver disease, including refractory and recurrent gastrointestinal bleeding, diuretic resistant volume overload, and hepatic encephalopathy failing standard therapies.
Hepatocellular Carcinoma (HCC) is a growing problem worldwide and the various treatment options can be challenging to understand and organize for the effective management of HCC. This symposium will focus on the multimodal options available to provide a “cure” for HCC. Four presentations will combine evidence based reviews and case discussions to help attendees understand where these modalities fit among other treatment options and how they can best be co-utilized to provide cutting-edge care for patients with HCC.
The last five years have seen HCV cure rates rise to more than 90 percent of all treated patients with cure rates for non-cirrhotic patients being almost 100 percent. These high cure rates should lead to the total eradication of HCV in the next two to three decades, provided there is universal access to treatment. In practice, however, politics, economics and regional insurance variation have not led to universal access to these curative therapies. The goals of this lecture are to discuss the status of HCV treatments in the context of the regional variability of these therapies by insurance type (public or private), review state policies and laws regarding access, and present successful strategies to increase acceptance of improved access to direct-acting anti-viral therapies.
The field of cholestatic liver diseases is rapidly evolving. This program will address gaps we have identified in routine clinical practice while also guiding the audience through recently published studies that actually impact management of patients with cholestatic liver diseases.
Knowledge gaps in PBC include timely diagnosis, especially in AMA-negative patients, using the proper dose of first line therapy (UDCA) and understanding that there is a subset of patients who don’t respond to UDCA and are candidates for second-line therapy with long-term monitoring. Recent studies such as POISE trial and the BEZURSO study will be discussed so that attendees can identify the best management options for non-responders to UDCA. Attendees will learn to risk-stratify patients with PBC to apply the best monitoring strategy in each individual case.
With respect to PSC, the program will aim to teach attendees about all management aspects which are often ignored since there is no approved pharmacological treatment. That will include diagnosis and management of biliary complications as well as surveillance for malignancies including colon cancer, gallbladder cancer and cholangiocarcinoma.
This lecture will cover the definition, pathophysiology, diagnosis, risk stratification and management of patients with ACLF.
The goal of this lecture is to highlight the current state-of-the-art on alcoholic liver disease and its severe form, alcoholic hepatitis. Participants will gain an understanding of the current knowledge as well as gaps in diagnosis, pathogenesis, natural history of ALD. Available and evolving treatment options will be discussed.